JPH0269160A - Gastrointestinal tube protecting and inorganic substance adsorption promoting composition - Google Patents
Gastrointestinal tube protecting and inorganic substance adsorption promoting compositionInfo
- Publication number
- JPH0269160A JPH0269160A JP63219927A JP21992788A JPH0269160A JP H0269160 A JPH0269160 A JP H0269160A JP 63219927 A JP63219927 A JP 63219927A JP 21992788 A JP21992788 A JP 21992788A JP H0269160 A JPH0269160 A JP H0269160A
- Authority
- JP
- Japan
- Prior art keywords
- absorption
- iron
- composition
- gastrointestinal tube
- oligosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 230000002496 gastric effect Effects 0.000 title claims abstract description 5
- 230000001737 promoting effect Effects 0.000 title claims description 7
- 239000000126 substance Substances 0.000 title abstract description 6
- 238000001179 sorption measurement Methods 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 claims abstract description 19
- 239000000835 fiber Substances 0.000 claims abstract description 9
- 241000196324 Embryophyta Species 0.000 claims abstract description 6
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 6
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 6
- 244000134552 Plantago ovata Species 0.000 claims abstract description 3
- 235000003421 Plantago ovata Nutrition 0.000 claims abstract description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims abstract 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims abstract 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 6
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical class [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims description 6
- 230000001681 protective effect Effects 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 230000004060 metabolic process Effects 0.000 abstract description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 abstract description 2
- 229940107187 fructooligosaccharide Drugs 0.000 abstract description 2
- 229910017053 inorganic salt Inorganic materials 0.000 abstract description 2
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 239000004606 Fillers/Extenders Substances 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 28
- 229910052742 iron Inorganic materials 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 238000009472 formulation Methods 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000002026 carminative effect Effects 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000007654 immersion Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 206010042220 Stress ulcer Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- 206010056325 Faecaloma Diseases 0.000 description 1
- 208000008415 Fecal Impaction Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011981 development test Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 229940082629 iron antianemic preparations Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明はカロリー摂取抑制、異常醗酵時での整腸、駆風
作用以外に、胃腸管保護性のある無機質吸収促進効果こ
とに胃腸管障害性等の副作用の発現を防止した無機質易
吸収促進性を有する組成物に係る。Detailed Description of the Invention (Field of Industrial Application) The present invention has an effect of suppressing calorie intake, regulating the intestines during abnormal fermentation, and carminative effect, as well as promoting mineral absorption with gastrointestinal tract protective properties, and preventing gastrointestinal disorders. The present invention relates to a composition that has the ability to promote easy absorption of minerals and prevents the occurrence of side effects such as sex.
（従来の技術）
ダイエタリーファイバーは、近年多種類のものが開発さ
れている。（特許公告６１−５２６６７号等）−部のも
のには宿便効果、コレステロールの吸収阻害効果が報告
されているか、これらは、増量による有毒物質の吸収を
阻害あるいは水分量の増加による場合が多く、それ自体
は消化吸収されず、良悪効果を期待したものかほとんど
である。(Prior Art) Many types of dietary fibers have been developed in recent years. (Patent Publication No. 61-52667, etc.) It has been reported that the fecal impaction effect and cholesterol absorption inhibiting effect are often caused by increasing the amount of the substance, inhibiting the absorption of toxic substances, or increasing the amount of water. It is not digested and absorbed by itself, and most of the time it is intended to have good or bad effects.
ダイエタリーファイバーの駆風効果にあっては腸内で消
化されないことから異常醗酵を抑制する意味で理論的に
は予測可能な事項である。Since the carminative effect of dietary fiber is not digested in the intestines, this is theoretically predictable in the sense of suppressing abnormal fermentation.
無機質ことに鉄は生体に対して多量に必要な元素であり
、鉄則は鉄欠乏性貧血の治療剤として使用されているが
、鉄は胃及び十二指腸上部において、酸性状態で吸収が
促進される。吸収を促進するなめ各種の有（幾鉄製剤か
開発されているが、吸収性を高めた場合、いずれら重危
な胃腸１ＩＪＩ害等、副作用か発現する欠陥かあった。Inorganic substances, particularly iron, is an element that is required in large amounts by living organisms, and Iron Rule is used as a therapeutic agent for iron deficiency anemia, but absorption of iron is promoted in acidic conditions in the stomach and upper duodenum. A variety of iron preparations have been developed to promote absorption, but they have some drawbacks, such as side effects such as serious gastrointestinal 1IJI damage, when absorption is increased.
また、その他の無機質例えば亜鈴、別等にあっては多量
に必要とするものではないが、鉄則と同様胃腸管壁に対
して潰瘍、びらん等の有害作用を及ぼずため、安全性の
高い投与方法の開発か望まれている状況であった６
（発明か解決しようとする課題）
発明四基らは、比較的多量に投与される、無機質ことに
鉄の胃腸管からの吸収方法の開発を研究した結果、既存
グイエタリーファイバーと糖類とこれら鉄則の組成物が
、胃腸障害を防止し、良好な鉄吸収か得られることを発
見し、さらには、亜鉛、銅等の腸管壁に対して有毒な無
機質類の吸収にあっても副作用の低減において極めて有
効であることを見出し本発明を完成するに至ったもので
ある。In addition, other inorganic substances, such as dumbbell, etc., are not required in large quantities, but as with the golden rule, they do not have harmful effects such as ulcers and erosions on the gastrointestinal tract wall, so they can be administered with high safety. 6 (Invention or problem to be solved) The four inventors sought to develop a method for absorbing minerals, especially iron, from the gastrointestinal tract, which is administered in relatively large amounts. As a result of research, it was discovered that the composition of existing nutritional fibers, sugars, and these iron rules can prevent gastrointestinal disorders and provide good iron absorption. The present invention was completed based on the discovery that this method is extremely effective in reducing side effects even in the absorption of toxic minerals.
また、既存のダイエタリーファイバー製品は駆風効果ど
ころか、製品によっては、腸内異常醗酵が発生ずる場合
もあり、また、冒満感、電解質代謝異常等の各種栄養素
の欠乏症か発生ずる場合もあるなめ、より安全性の高い
製剤の出現か望まれている現状であった。In addition, existing dietary fiber products do not have a carminative effect; some products may cause abnormal fermentation in the intestines, and may also cause various nutrient deficiencies such as a feeling of fullness and abnormal electrolyte metabolism. The current situation is that it is hoped that a safer formulation will emerge.
本発明はこれらの問題点についてら完全に解決し、タイ
エンド食品として整腸効果ら高く、栄養的には鉄吸収促
進効果の両面を合せ持った、機能性組成物を提供するこ
とを目的としたもの一ζある。The purpose of the present invention is to completely solve these problems and provide a functional composition that has both a high intestinal regulation effect as a tie-end food and a nutritionally effective iron absorption promoting effect. There is one thing.
（課題を解決するための手段）
本発明は上記知見に基ついて、ａ、植物由来の４１１線
維、ｂ、オリゴ糖またはその３Ａ導１本、Ｃ１無機塩、
以上ａ〜ｃからなる胃腸管保護性無機質吸収促進性組成
物を提供するものである。(Means for Solving the Problems) Based on the above findings, the present invention provides: a) 411 fiber derived from plants; b) oligosaccharide or one 3A chain thereof; C1 inorganic salt;
The present invention provides a gastrointestinal tract protective mineral absorption promoting composition consisting of the above components a to c.
各種製剤調整にあたっては、必要成分として、植物由来
の粗線維の含有量が全製剤量の２０〜８０？≦、オリゴ
楯または誘導体５〜４０％、鉄塩０．０１〜５％の範囲
にあるのか好ましい。When preparing various formulations, the content of plant-derived crude fiber as a necessary ingredient should be 20 to 80% of the total formulation amount. It is preferable that the content is in the range of ≦5 to 40% of the oligo shield or derivative and 0.01 to 5% of the iron salt.
なお、その他の添加成分は一般の増量剤以外に、本発明
の組成分と生物学的にあるいは、化学的に相互作用を起
こさない安定な成分てあれば、適当に配合することがで
きる。Other additive components other than general fillers can be appropriately blended as long as they are stable components that do not interact biologically or chemically with the components of the present invention.
（発明の効果）
本発明による組成物は、胃腸管に対して、全く悪影響を
与えることなく鉄の吸収を促進し、食物との併用使用の
場合は高カロリー栄謄素の吸収を抑制し、逆にビタミン
等代謝関連物質量の吸収を促進し、また、腸内異常醗酵
を防止、駆風効果を合せ持つ、安全性の高い組成物であ
ることが後述する各種試験によって立証された。(Effects of the Invention) The composition according to the present invention promotes the absorption of iron without having any adverse effects on the gastrointestinal tract, suppresses the absorption of high-calorie nutrients when used in combination with food, On the contrary, various tests described below have proven that it is a highly safe composition that promotes the absorption of metabolism-related substances such as vitamins, prevents abnormal intestinal fermentation, and has a carminative effect.
（実施例）
■）薬効試験
鉄則による 瘍助長抑 効果試験
体重２００〜３００ ｇウィスター系雄性ラット−群１
０匹をｆ重用し、２４時間絶食後、製剤例１の試験組成
物５００■／ ｋｚを経口投与し、水浸ストレス潰瘍、
塩酸エタノールｉｉ１瘍の発生試験を行った。(Example) ■) According to the golden rule of drug efficacy test: Tumor promotion inhibition effect test Weight: 200-300 g Wistar male rats - Group 1
After fasting for 24 hours, 500 μ/kz of the test composition of Formulation Example 1 was orally administered to 0 mice to treat water immersion stress ulcers,
Hydrochloric acid ethanol II1 tumor development test was conducted.
■水浸ス１ヘレス潰瘍；試験組成物を投与の３０分後拘
束ケージに入れ胸部まで水浸温度２３°Ｃ６時間拘束す
る。■Water immersion 1 Heres ulcer; Thirty minutes after administration of the test composition, the test composition was placed in a restraint cage and restrained up to the chest at a water immersion temperature of 23°C for 6 hours.
■塩酸エタノール潰瘍；試験組成物を投与後、６０分後
に１５０ｎＨ塩酸／６０％エタノール液を１ ｒｎＱ経
口投与し１時間拘束する。(2) Hydrochloric acid ethanol ulcer: 60 minutes after administering the test composition, 1 rnQ of 150 nH hydrochloric acid/60% ethanol solution is orally administered and restrained for 1 hour.
胃を摘出し１％ホルマリン液で組織固定し、胃損傷の長
さを測定し、５ｔｕｄｌｔｓづ検定により漫錐度を求め
た。結果は以下の表１の通りであり本発明組成物に軽度
の潰瘍予防効果とともに、クエン酸鉄による潰瘍助長作
用を抑制する効果のあることか判明した。The stomach was removed, the tissue was fixed with 1% formalin solution, the length of the gastric injury was measured, and the degree of circular conus was determined by the 5tudlts test. The results are shown in Table 1 below, and it was found that the composition of the present invention had a mild ulcer preventive effect as well as an effect of suppressing the ulcer promoting effect caused by iron citrate.
表１ 潰瘍浸蝕度（？≦）
■ストレス潰瘍群 ■塩酸潰瘍群
試験組成物
Ａ）対象群
Ｂ）試験薬投与群
ａ）製造ρ１１
組成物
ｂ）植物線維 ８１
（プランタゴオバタ種皮）
Ｃ）オリゴ糖
（フラクトオリゴ糖）
ｄ）アミノ酸類
（アルギン酸Ｎａ）
ｅ）クエン酸鉄
Ｃ）抗潰瘍刑投与群
（シメチジン１００■、／ｋｇ）２５ ７０
鉄吸収促進試験
秩欠乏食で１ケ月にわたり飼育した体重２００ｇ前後の
ウィスター系貧血性うｙ ｈ （１群５匹）を用い、試
１検絹成掬（クエン酸鉄として１日５００／■）を飼Ｉ
Ｉ添加の形で１週間与え、尾静脈から採血し高速遠心毛
細管法により、ヘラ１ヘクリント値を測定し口１！度を
観察した。結果は全例ともにヘマトクリ・／１へ値の正
常値に近い回復が７６められな。簡便な試験法で４６り
貯蔵鉄量について詳潤に検討したわけではないか、ヘマ
トクリット値の上昇がクエン酸鉄の投与によるものであ
り、吸収が行われていることは明白て゛あった。Table 1 Ulcer erosion degree (?≦) ■ Stress ulcer group ■ Hydrochloric acid ulcer group Test composition A) Subject group B) Test drug administration group a) Production ρ11 Composition b) Plant fiber 81 (Plantago ovata seed coat) C) Oligosaccharide (Fructooligosaccharide) d) Amino acids (Na alginate) e) Iron citrate C) Anti-ulcer treatment group (cimetidine 100cm/kg) 25 70
Iron absorption promotion test Using anemic Wistar breeds (5 animals per group) with a weight of around 200 g raised on a chichi-deficient diet for 1 month, the first test was conducted using Kinuseiyuki (500 iron citrate per day). I keep it
Blood was collected from the tail vein and measured by high-speed centrifugal capillary method to measure the heclint level. I observed the degree. The results showed that in all cases, the hematocrit level returned to 1/1, which is close to the normal value. It was clear that the increase in hematocrit value was due to the administration of iron citrate, and absorption was occurring, although the amount of stored iron was not investigated in detail using a simple test method.
２ ） 製斉１］例
製剤例１
プランタゴオバタ種皮１２０ ｇ、クエン酸第−鉄すｌ
−リウム２ｇ、フラクトオリゴ１ｆｉ１０ｇ、還元麦芽
＠１０ｇ、アルギン酸ナトリウム５８ｇをとり、混合し
、水及びエタノールを用いて常法により湿式造粒し、乾
燥させて顆粒状のグイエタリーファイハー剤Ｉ成１勿を
得た、
製斉り（列 ２
製剤例１で得た顆粒状のグイエタリーファイバー組成’
Ｆｈ９８ｇをとり、シュカーエステル２ｇを加えて混合
した後、圧縮成型し錠剤状のダイエタリーファイバー組
成物を得た。2) Preparation Example 1 Preparation Example 1 Plantago Obata seed coat 120 g, ferrous citrate salt
- Take 2 g of Limeium, 10 g of Fructooligo 1fi, 10 g of reduced malt, and 58 g of sodium alginate, mix them, wet granulate them using water and ethanol in a conventional manner, and dry them to obtain granular Guetary Fifer agent I Form 1. As a result, the production process (Row 2 Granular guietary fiber composition obtained in Formulation Example 1)
98 g of Fh was taken, 2 g of Shukar ester was added thereto, mixed, and then compression molded to obtain a tablet-shaped dietary fiber composition.
製剤安定性試験
製剤例１及び２を試料とし、苛酷条件下（５０°Ｃ３０
日間及び４０°Ｃ相対湿度７５％３０日間）における鉄
の安定性を調べた。Formulation stability test Formulation examples 1 and 2 were used as samples under severe conditions (50°C, 30°C).
The stability of iron at 40°C and 75% relative humidity for 30 days was investigated.
［鉄の定量法コ
試料を５００〜５５０°Ｃで乾式灰化した後、残留物を
希塩酸に溶かして調整した試料溶液につき、次の条件で
原子吸光光度法により鉄の定量を行った。[Determination method of iron] After the sample was dry-ashed at 500 to 550°C, the residue was dissolved in dilute hydrochloric acid to prepare a sample solution, and iron was determined by atomic absorption spectrometry under the following conditions.
光 源： 鉄中空陰衝ランフ。Light source: Iron hollow shadow lamp.
バーナー： スリブ１〜バーナー
燃焼カス； アセチレン・空気フレーム測定波長：
２４８．３ｒｒｎ
結果は下記の表に示すとおり、いずれの製剤ム安定であ
り、外観においても変化はＬめらｔしながつた。Burner: Slab 1 to burner combustion residue; Acetylene/air flame measurement wavelength:
248.3 rrn As shown in the table below, all formulations were stable, and there was little change in appearance.
Claims (2)
物。(1) A gastrointestinal tract protective mineral absorption promoting composition consisting of a, plant-derived crude fiber b, oligosaccharide or its derivative c, and inorganic salts a to c.
８０重量％。 ｂ、フラクトオリゴ糖または還元麦芽糖からなるオリゴ
糖またはその誘導体５〜４０重量％。 ｃ、クエン酸鉄塩からなる０．０１〜５重量％。 以上ａ〜ｃからなる特許請求の範囲第１項に記載の胃腸
管保護性無機質吸収促進性組成物。(2)a, Crude fibers consisting of Plantago ovata seed coat 20~
80% by weight. b. 5 to 40% by weight of fructooligosaccharides or oligosaccharides consisting of reduced maltose or derivatives thereof; c, 0.01-5% by weight consisting of iron citrate salts. The composition for promoting gastrointestinal tract-protective mineral absorption according to claim 1, comprising the above a to c.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63219927A JPH0269160A (en) | 1988-09-02 | 1988-09-02 | Gastrointestinal tube protecting and inorganic substance adsorption promoting composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63219927A JPH0269160A (en) | 1988-09-02 | 1988-09-02 | Gastrointestinal tube protecting and inorganic substance adsorption promoting composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0269160A true JPH0269160A (en) | 1990-03-08 |
Family
ID=16743200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63219927A Pending JPH0269160A (en) | 1988-09-02 | 1988-09-02 | Gastrointestinal tube protecting and inorganic substance adsorption promoting composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0269160A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2773713A1 (en) * | 1998-01-16 | 1999-07-23 | Investigations Therapeutiques | Compositions for the treatment of iron deficiency containing an iron salt, lactoferrin, and a fructo-oligosaccharide |
| JP2002027946A (en) * | 2000-07-14 | 2002-01-29 | Pola Chem Ind Inc | Mineral absorption promoter and composition containing the same |
| WO2007117175A1 (en) * | 2006-04-10 | 2007-10-18 | Avva Pharmaceuticals Ag | Pharmaceutical composition of enterosorbent and prebiotics, dosage forms, and the method for prevention and treatment of gastrointestinal disorders |
-
1988
- 1988-09-02 JP JP63219927A patent/JPH0269160A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2773713A1 (en) * | 1998-01-16 | 1999-07-23 | Investigations Therapeutiques | Compositions for the treatment of iron deficiency containing an iron salt, lactoferrin, and a fructo-oligosaccharide |
| EP0938850A1 (en) * | 1998-01-16 | 1999-09-01 | Investigations therapeutiques essais cliniques services société à Responsabilité Limitée | Food or pharmaceutical composition and preparations containing the same |
| JP2002027946A (en) * | 2000-07-14 | 2002-01-29 | Pola Chem Ind Inc | Mineral absorption promoter and composition containing the same |
| WO2007117175A1 (en) * | 2006-04-10 | 2007-10-18 | Avva Pharmaceuticals Ag | Pharmaceutical composition of enterosorbent and prebiotics, dosage forms, and the method for prevention and treatment of gastrointestinal disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69910559T2 (en) | NEW FAT ANALOGS FOR THE TREATMENT OF OBESITY | |
| Koruda et al. | Parenteral nutrition supplemented with short-chain fatty acids: effect on the small-bowel mucosa in normal rats | |
| AU628514B2 (en) | Inhibitive agent against activity of alpha-amylase | |
| US3383281A (en) | Method for binding bile acids in vivo | |
| Coşkun et al. | Protective effects of quercetin, a flavonoid antioxidant, in absolute ethanol-induced acute gastric ulcer | |
| Gürbüz et al. | Evaluation of the anti-ulcerogenic effect of sesquiterpene lactones from Centaurea solstitialis L. ssp. solstitialis by using various in vivo and biochemical techniques | |
| US20070202204A1 (en) | Plant extract mixtures and their uses | |
| CA2564326A1 (en) | Nutritional composition which promotes weight loss, burns calories, increases thermogenesis, supports energy metabolism and/or suppresses appetite | |
| Tebib et al. | Effects of dietary grape seed tannins on rat cecal fermentation and colonic bacterial enzymes | |
| US8669292B2 (en) | Therapeutic formulation | |
| WO2020059995A1 (en) | Health drink composition for preventing liver damage caused by alcohol while providing excellent hangover relief | |
| WO2019017603A2 (en) | Composition for improving hangovers containing trapa japonica flerow extract and curcumin as active ingredient | |
| Wostmann et al. | Total serum and liver cholesterol in germfree and conventional male rats | |
| JP2021519344A (en) | Compositions and methods for the treatment of diarrhea | |
| JPH0269160A (en) | Gastrointestinal tube protecting and inorganic substance adsorption promoting composition | |
| KR101045279B1 (en) | Composition of functional food with weight loss effect | |
| KR102040809B1 (en) | Calcium complex comprising mussel shell and oligosaccharide and uses thereof | |
| JP2005512956A (en) | Use of ginkgo biloba extract to produce a medicament intended to treat muscle deficiency | |
| CN115569129A (en) | Carbazoline calcium solid preparation and preparation method thereof | |
| CN114732783A (en) | Doxycycline hydrochloride solution and preparation method and application thereof | |
| WO2008107182A2 (en) | Formulations of al pha-amylas e inhibitors of p. vulgaris with alpha-glucos idade inhibitores of s. oblonga or s. reticulata useful in the treatment of diabetes and obesity | |
| US20220143192A1 (en) | Compositions comprising vitamins/minerals in a polyphenolic matrix, methods and uses thereof | |
| Sklan et al. | Site of bile acid absorption in the rat | |
| JPH07112979B2 (en) | Active oxygen free radical scavenger | |
| DE2759108A1 (en) | USE OF ALPHA -MERCAPTO-BETA-ARYL-ACRYLIC ACIDS IN INCREASING THE ZINC CONTENT IN SERUM AND TISSUE |